We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.92 | 2.22% | 42.36 | 42.84 | 42.275 | 42.70 | 2,623,620 | 19:07:55 |
From May 2019 to May 2024
Rory Gallivan
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday a study of its Mekinist and Tafinlar drugs showed favorable results compared with another treatment in patients with the skin cancer Melanoma.
The drug company said a committee recommended the study be stopped early having "demonstrated an overall survival benefit for the trametinib and dabrafenib combination compared to vemurafenib that crossed the pre-specified efficacy stopping boundary."
Shares at 1311 GMT, up 4 pence, or 0.3%, at 1,548 pence, valuing the company at GBP75 billion ($128.5 billion).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
